Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications. We aimed to estimate the cost-effectiveness of sorafenib and TACE in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuling, Peng, Zhenwei, Wei, Mengchao, Liu, Weifeng, Dai, Zihao, Wang, Haibo, Mei, Jie, Cheong, Mingfong, Zhang, Hanmei, Kuang, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887167/
https://www.ncbi.nlm.nih.gov/pubmed/29621988
http://dx.doi.org/10.1186/s12885-018-4308-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887167/
https://www.ncbi.nlm.nih.gov/pubmed/29621988
http://dx.doi.org/10.1186/s12885-018-4308-7

Ejemplares similares